Management of chemotherapy-induced diarrhea;Management chemotherapieinduzierter diarrhöen

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 6, 2004, Pages 527-538

  Schultz, M ^a   Scholmerich J ^a   Kullmann, Frank ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

5 fluorouracil; Chemotherapy; CPT 11; Diarrhea; Glutamine; Irinotecan; Loperamide; Octreotide

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ATROPINE; BUDESONIDE; CAPECITABINE; CIPROFLOXACIN; CISPLATIN; COLESTYRAMINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GRANISETRON; INTERFERON; IRINOTECAN; LEVAMISOLE; LOPERAMIDE; NEOMYCIN; OCTREOTIDE; ONDANSETRON; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; THALIDOMIDE; TOPOTECAN; TROPISETRON; UNINDEXED DRUG;

ALGORITHM; ALOPECIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SAFETY; EDEMA; ENTERITIS; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NEUROPATHY; PATHOPHYSIOLOGY; REHYDRATION; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING;

ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DIARRHEA; DRUG THERAPY; FLUOROURACIL; HUMANS; LOPERAMIDE; NEOPLASMS; OCTREOTIDE; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES;

EID: 3042825603     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812982     Document Type: Review

References (109)

1. de Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-4354
2. Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-1426
3. Engelking C, Wickham R, Iwamoto R. Cancer-related gastrointestinal symptoms: Dilemmas in assessment and management. Dev Support Cancer Care 1996; 1: 3-10
4. Hryniuk W, Figueredo A, Goodyear M. Application of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14 (Suppl): 3-11
5. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288
6. Norton L. Evolving concepts in the systemic drug therapy of of breast cancer. Semin Oncol 1997; 24 (Suppl): S10-3-S10-10
7. Regnard CFB, Tempest S. A guide to symptom relief in advanced cancer. Manchester: Haigh and Hockland, 1992
8. Sykes NP. Constipation and diarrhea. In: Doyle D, Hanks GW, MacDonald N (Hrsg). Oxford textbook of palliative medicine. Oxford: Oxford Medical, 1998: 299-310
9. Levy MH. Constipation and diarrhea in cancer patients. Cancer Bull 1991; 43: 412-422
10. Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000; 5: 250-259
11. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-1311
12. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-944
13. Laufman LR, Bukowski RM, Collier MA et al. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993; 11: 1888-1893
14. Macdonald JS. Adjuvant therapy for colon cancer. CA Cancer J Clin 1997; 47: 243-256
15. Wadler S, Benson AB III, Engelking C et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998; 16: 3169-3178
16. Mercadante S. Diarrhea in terminally ill patients: pathophysiology and treatment. J Pain Symptom Manage 1995; 10: 298-309
17. Fernandez-Banares F, Villa S, Esteve M et al. Acute effects of abdominopelvic irradiation on the orocecal transit time: its relation to clinical symptoms, and bile salt and lactose malabsorption. Am J Gastroenterol 1991; 86: 1771-1777
18. Erickson BA, Otterson MF, Moulder JE et al. Altered motility causes the early gastrointestinal toxicity of irradiation. Int J Radiat Oncol Biol Phys 1994; 28: 905-912
19. Sher ME, Bauer J. Radiation-induced enteropathy. Am J Gastroenterol 1990; 85: 121-128
20. Baskerville A, Batter-Hatton D. Intestinal lesions induced experimentally by methotrexate. Br J Exp Pathol 1977; 58: 663-669
21. de Roy van Zuidewijn DB, Schillings PH et al. Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 1992; 56: 96-107
22. Milles SS, Muggia AL, Spiro HM. Colonic histologic changes induced by 5-fluorouracil. Gastroenterology 1962; 43: 391-399
23. Advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903
24. Kohne CH, Wils A, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of research and treatment of cancer gastrointestinal group study 40 952. J Clin Oncol 2003; 21: 3721-3228
25. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-1972
26. Madisch A, Wiedbrauck F, Marquard F et al. 5-Fluorouracil-induced colitis - a review based upon consideration of 6 cases. Z Gastroenterol 2002; 40: 59-66
27. Daniele B, Secondulfo M, De Vivo R et al. Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol 2001; 32: 228-230
28. Tuchman M, Stoeckeler JS, Kiang DT et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985; 313: 245-249
29. Harris BE, Song R, Soong SJ et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201
30. Van Kuilenburg AB, Vreken P, Abeling NG et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9
31. Allegra CJ. Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil? Clin Cancer Res 1999; 5: 1947-1949
32. Di Paolo A, Danesi R, Falcone A et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301-1306
33. Stephan F, Etienne MC, Wallays C et al. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 1995; 99: 685-688
34. Takimoto CH, Lu ZH, Zhang R et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2: 477-481
35. Milano G, Etienne MC. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit 1996; 18: 335-340
36. Fukuoka M, Niitani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20
37. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11: 909-913
38. Abigerges D, Armand JP, Chabot GG et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-449
39. Dodds H, Rivory LP. The mechanisms for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 1999; 56: 1346-1353
40. Blandizzi C, Danesi R, De Paolis B et al. Cholinergic toxic syndrome by the anticaner drug irinotecan: Acetylcholinesterase does not play a major role. Clin Pharmacol Ther 2002; 71: 263-271
41. Blandizzi C, De Paolis B, Colucci R et al. Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 2001; 132: 73-84
42. Kawato Y, Sekiguchi M, Akahane K et al. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 1993; 45: 444-448
43. Takasuna K, Kasai Y, Kitano Y et al. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Nippon Yakurigaku Zasshi 1995; 105: 447-460
44. Kaneda N, Nagata H, Furuta T et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-1720
45. Kawato Y, Aonuma M, Hirota Y et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-4191
46. Charman WN, Porter CJ, Mithani S et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997; 86: 269-282
47. Bugaut M. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp Biochem Physiol B 1987; 86: 439-472
48. Kobayashi K, Bouscarel B, Matsuzaki Y et al. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 1999; 83: 491-496
49. Atsumi R, Okazaki O, Hakusui H. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7] -indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. Biol Pharm Bull 1995; 18: 1114-1119
50. Araki E, Ishikawa M, Iigo M et al. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993; 84: 697-702
51. Kobayashi K, Shinbara A, Kamimura M et al. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother Pharmacol 1998; 42: 53-58
52. Takeda Y, Kobayashi K, Akiyama Y et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001; 92: 269-275
53. Takasuna K, Hagiwara T, Hirohashi M et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-3757
54. Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854
55. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica London 1991; 21: 1159-1169
56. Kehrer DF, Sparreboom A, Verweij J et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7: 1136-1141
57. Wasserman E, Myara A, Lokiec F et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049-1051
58. Gupta E, Lestingi TM, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725
59. Taminiau JA, Gall DG, Hamilton JR. Response of the rat small-intestine epithelium to methotrexate. Gut 1980; 21: 486-492
60. Benson AB III, Goldberg RM. Optimal use of the combination of irinotecan and 5-Fluorouacil. Sem Oncol 2003; 30: 68-77
61. Saltz LB, Cox JV, Blanke CD et al. Iriontecan plus fluorouracil and leukovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914
62. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
63. National Cancer Institute Common Toxicity Criteria for Grading the Severity of Diarrhea. National Cancer Institute: Investigator's Handbook: A manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI. In: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute (Hrsg). Bethesda, MD: National Cancer Institute, 1993
64. Mathijssen RH, Verweij J, de Bruijn P et al. Effect of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249
65. O'Malley ME, Wilson SR. US of gastrointestinal tract abnormalities with CT correlation. Radiographics 2003; 23: 59-72
66. Du Pont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997; 92: 1962-1975
67. Bavaro MF. Neutropenic enterocolitis. Curr Gastroenterol Rep 2002; 4: 297-301
68. Kouroussis C, Samonis G, Androulakis N. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol 2000; 23: 309-313
69. Martz CH. Diarrhea. In: Groenwald SL, Frogge MH, Goodmann M et al (Hrsg). Cancer Symptom Management. Boston, MA: Jones & Barlett, 1996: 498-520
70. Hogan CM. The nurse's role in diarrhea management. Oncol Nurs Forum 1998; 25: 879-886
71. Schiller LR. Review article: anti-diarrheal pharmacology and therapeutics. Aliment Pharmacol Ther 1995; 9: 87-106
72. Olm M, Gonzales FJ, Garcia-Valdecasas JC et al. Necrotising colitis with perforation in diarrhoic patients treated with loperamide. Eur J Clin Pharmacol 1991; 40: 415-416
73. Ericsson CD, Johnson PC. Safety and efficacy of loperamide. Am J Med 1990; 88: 10S-14S
74. Catimel G, Chabot GG, Guastalla JP et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133-140
75. Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-221
76. Merrouche Y, Extra JM, Abigerges D et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol 1997; 15: 1080-1086
77. Gandia D, Abigerges D, Armand JP et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11: 196-197
78. Cooper JC, Williams NS, King RF et al. Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 1986; 73: 128-131
79. Dueno MI, Bai JC, Santangelo WC et al. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987; 32: 1092-1096
80. Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 1999; 60 (Suppl 2): 42-46
81. Cascinu S, Fedeli A, Fedeli SL et al. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 1994; 51: 70-73
82. Cascinu S, Fedeli A, Fedeli SL et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 148-151
83. Cascinu S, Fedeli A, Fedeli SL et al. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28: 482-483
84. Barbounis V, Koumakis G, Vassilomanolakis M et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Supp Care Cancer 2001; 9: 258-260
85. Meropol NJ, Blumenson LE, Creaven PJ. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol 1998; 21: 135-138
86. van der Hulst RR, van Kreel BK, von Meyenfeldt MF et al. Glutamine and the preservation of gut integrity. Lancet 1993; 341: 1363-1365
87. Tremel H, Kienle B, Weilemann LS et al. Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal function in the critically ill. Gastroenterology 1994; 107: 1595-1601
88. Fox AD, Kripke SA, De Paula J et al. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr 1988; 12: 325-331
89. Rombeau JL. A review of the effects of glutamine-enriched diets on experimentally induced enterocolitis. JPEN J Parenter Enteral Nutr 1990; 14 (4 Suppl): 100S-105S
90. Decker-Baumann C, Buhl K, Frohmuller S et al. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 1999; 35: 202-207
91. Savarese D, Al-Zoubi A, Boucher J. Glutamine for irinotecan diarrhea. J Clin Oncol 2000; 18: 450
92. Savarese DMF, Savy G, Vahdat L et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003; 29: 501-513
93. Ikegami T, Ha L, Arimori K et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002; 62: 179-187
94. Takeda Y, Kobayashi K, Akiyama Y et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001; 92: 269-275
95. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thalidomide. BioDrugs 2001; 15: 681-703
96. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277
97. Govindarajan R, Heaton KM, Broadwater R et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000; 356: 566-567
98. Lenfers BH, Loeffler TM, Droege CM et al. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10: 1251-1253
99. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl 2000; 113: 37-45
100. Bailey LD Jr, Stewart WR Jr, McCallum RW. New directions in the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20: 335-349
101. Steadman CJ, Talley NJ, Phillips SF et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992; 67: 732-738
102. Nightingale JM, Walker ER, Burnham WR et al. Short bowel syndrome. Digestion 1990; 45 (Suppl 1): 77-83
103. Mennie AT, Dalley VM, Dinneen LC et al. Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet 1975; 2: 942-943
104. Simon DM, Cello JP, Valenzuela J et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995; 108: 1753-1760
105. Weh HJ, Zschaber R, Braumann D et al. A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA in untreated patients with metastatic colorectal carcinoma. Onkologie 1998; 21: 403-407
106. Porschen R, Bermann A, Loffler T et al. Fluorouracil plus leukocorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001; 19: 1787-1794
107. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
108. Koehne CH, van Cutsem E, Wils A. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of the EORTC GI Group Study 40 986. Proc Am Soc Clin Oncol 2003; 21: A1018
109. De Gramont A, Figer A, Seymour M et al. Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947